



REGENXBIO to Participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day

February 2, 2017 12:01 PM EST

ROCKVILLE, Md., Feb. 02, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV[®] Technology Platform, today announced that it will participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day. The conference will take place on Tuesday, February 14, 2017 at the JW Marriott Essex House New York in New York, NY. REGENXBIO representatives will be holding one-on-one meetings at the conference.

About REGENXBIO

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV[®] Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing *in vivo* gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform Licensees. REGENXBIO and its licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

CONTACT: [

Investors [

Heather Savelle, 646-395-3734

heather@argotpartners.com

Media [

Laura Bagby, 312-448-8098

lbagby@6degreespr.com



REGENXBIO Inc.